[Studies on the onset of effect of reproterol following inhalation from a metered aerosol (author's transl)].
According to a uniform trial procedure, the broncholytic efficacy of the new beta2-adrenergic 7-(3-[2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino]-propyl)-theophylline (reproterol, Bronchospasmin) was tested in a total of 21 patients afflicted with airways obstruction in two lungfunction laboratories. The IGV, Ras and SGaw were calculated by bodyplethysmography before and 1,3 and  5 min following of 2 puffs from an aerosol container. Excellent and highly significantly bronchodilation was shown already 1 min post  inhalation, which further increased during testing time and with which results of subjective criteria for dyspnoeic changes correspond. The preparation may therefore be recommended for therapy of dyspnoeic attacks in an aerosol form equipped with metering valves.
D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010627:Phenethylamines / Q000627:therapeutic use*; D010993:Plethysmography, Whole Body; D013997:Time Factors; D014970:Xanthines / Q000627:therapeutic use*
D000336:Aerosols; D001993:Bronchodilator Agents; D010627:Phenethylamines; D014970:Xanthines
Untersuchungen zum Wirkungseintritt nach Inhalation von Reproterol aus einem Dosier-Aerosol